S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:THOR

Synthorx Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$67.99
0.00 (0.00%)
(As of 01/23/2020)
Add
Compare
Today's Range
$67.99
$67.99
50-Day Range
$67.99
$67.99
52-Week Range
$11.05
$71.90
Volume
N/A
Average Volume
474,507 shs
Market Capitalization
$2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthorx and its competitors with MarketBeat's FREE daily newsletter.


Synthorx logo

About Synthorx

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:THOR
CUSIP
88517530
Fax
N/A
Employees
48
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$6.72 per share

Profitability

Net Income
$-56.61 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$2.20 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/05/2019
Today
1/20/2022

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

1083rd out of 1,415 stocks

Pharmaceutical Preparations Industry

524th out of 682 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Synthorx (NASDAQ:THOR) Frequently Asked Questions

How were Synthorx's earnings last quarter?

Synthorx, Inc. (NASDAQ:THOR) posted its quarterly earnings data on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.12.
View Synthorx's earnings history
.

Who are Synthorx's key executives?

Synthorx's management team includes the following people:
  • Dr. Laura K. Shawver, CEO, Pres & Director (Age 62, Pay $606.48k)
  • Dr. Floyd E. Romesberg, Founder (Age 54, Pay $2.68k)
  • Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 57, Pay $457.71k)
  • Dr. Joseph Leveque, Chief Medical Officer (Age 59, Pay $448.76k)
  • Mr. Tighe M. Reardon C.F.A., CPA, CPA, Acting Chief Financial Officer (Age 44)

What other stocks do shareholders of Synthorx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Lululemon Athletica (LULU), Micron Technology (MU) and Novartis (NVS).

When did Synthorx IPO?

(THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Synthorx's stock symbol?

Synthorx trades on the NASDAQ under the ticker symbol "THOR."

What is Synthorx's stock price today?

One share of THOR stock can currently be purchased for approximately $67.99.

How much money does Synthorx make?

Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56.61 million in net income (profit) each year or ($6.59) on an earnings per share basis.

How many employees does Synthorx have?

Synthorx employs 48 workers across the globe.

What is Synthorx's official website?

The official website for Synthorx is www.synthorx.com.

Where are Synthorx's headquarters?

How can I contact Synthorx?

Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.